Tiziana Life Sciences is a clinical-stage biotechnology company developing transformative therapies for neurodegenerative and neuroinflammatory diseases, operating a lean virtual research model. Its flagship asset, foralumab, is a fully human anti-CD3 monoclonal antibody administered intranasally that modulates immune response and induces immune tolerance; the company is advancing foralumab through clinical trials in multiple indications including multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also maintains a supporting asset, TZLS-501, an anti-IL-6 receptor antibody that addresses systemic and localized inflammation, while prioritizing foralumab development backed by extensive patent protection extending to the mid-2040s.